



**Jun Xiang, PhD**  
*General Manager  
ChemPartner Biologics  
(Shanghai) Co., Ltd.*

**Jun Xiang**, has near 20 years' experience in R&D of biological drug products, and is the General Manager of ChemPartner Biologics (Shanghai) Co., Ltd. which provides one-stop CDMO services for biologics, covering from development of cell line, cell culture and purification process, and formulation to pilot-scale and commercial scale manufacturing. Prior to joining CPB, Dr. Xiang was a Sr. VP of Biotechnology Institute of Shanghai CP Guojian (Now name changed to Sunshine Guojian Pharmaceutical (Shanghai) Co. Ltd.). He was responsible for research and development of novel formulations and drug delivery systems as well as late stage production processes for antibody drug products. He was also in charge of the entire development of antibody-drug conjugates (ADC), and has established ADC technology platform in CP Guojian along with completion of one ADC drug product IND filing. Dr. Xiang previously worked as a Staff Scientist at Bayer HealthCare Pharmaceuticals in US. He has tremendous experience in late stage development of biological drug products, especially in the various CMC fields. He served as the President of Chinese American Biopharmaceutical Society (CABS) from 2005 to 2006, and was a Board member of CABS from 2004 to 2018. He was also the Chief Managing Editor of the journal Trends in Bio/pharmaceutical Industrial from 2008 to 2011.



**Alex Zhang, PhD, MBA**  
CEO

**Alex Zhang**, is the CEO of Hanhai Silicon Valley., an early stage investor and cross-border accelerator for startups in San Francisco Bay Area. Prior to Hanhai, Alex was the Managing Partner of Enverest, LLC., a Silicon Valley-based innovation solutions and investment advisory firm with branch offices in China and Singapore. Prior to co-founding Enverest, Dr. Zhang spent nearly five years at Thermo Fisher Scientific, where he was responsible for 4 business development deals exceeding \$10 M, and played a key role in several billion-dollar acquisitions in MedTech. From 2001 to 2009, Dr. Zhang was a Senior Scientist at Tularik Inc. (acquired by Amgen in 2004), where he led drug discovery endeavors in oncology, cardiovascular and metabolic diseases therapeutic areas.

Dr. Zhang received MBA degree at Cornell University, PhD in Organic and Analytical Chemistry at Texas A&M University, and BS in Chemistry at Shandong University. During his graduate research, he focused on the design and synthesis of therapeutic peptoids, as well as biological mass spectrometry. His research has led to publication of more than 20 peer reviewed articles and 4 patents.

Dr. Zhang has served multiple leadership roles in the Executive Council of CABS, including as the President in 2017-18. Over the past decade, Dr. Zhang has advised a number of successful MedTech and digital health startups based in Silicon Valley.

# iDNA



**Huijun Zhou, PhD,  
FACMG**  
*Founder & CEO*

**Huijun Zhou** Dr. Huijun Zhou is CEO and co-founder of Doctor Chain and [iDNA.com.cn](http://iDNA.com.cn). Dr. Zhou received her Ph.D. in molecular biology and genetics from Cornell University and completed her post-doctoral medical genetics training at the Stanford University School of Medicine. She is a clinical molecular geneticist, board-certified by the American Board of Medical Genetics. She is the Program Chair of Chinese American BioPharmaceutical Society (CABS) Entrepreneurship Club.

# Deloitte.



**Vivien Wang, MS**  
*Partner*  
*International Tax*

**Vivien Wang** has over 20 years of public accounting and international tax experiences, providing tax consulting, compliance and tax accounting assurance services to various high-tech, biotech and venture capital clients. Her experience includes structuring and globally managing both U.S. inbound and outbound investments. Vivien specializing in the IPO restructuring, merger and acquisition integration and implementation of worldwide IP migrations and supply chain strategies for multinational clients. Vivien is our US Inbound Practice leader for the West Region, focusing on serving foreign company's investments in the US through both M&A and greenfield investment. Vivien is also the National Tax Leader of Deloitte's US Chinese Services Group, specializing in China strategy planning for US companies and investment funds and US inbound investment planning for China based investors. In this role, Vivien serves many leading Asia based private equity and venture capital firms, and technology companies and their investments in the U.S. Vivien obtained her MS in Taxation at San Jose State University, BS in Accounting from University of Utah and BA in International Finance, Shenzhen University.



**Michael Liu Su, MS, JD**  
*Attorney*  
*Intellectual Property*  
*Law*

**Michael Liu Su** is an attorney at intellectual property law firm Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. Based in Finnegan's Palo Alto office, Mike's practice spans both patent and trade secret matters, involving industries such as biotechnology, pharmaceuticals, chemical, medical devices, and computer technology. His litigation experience includes representing clients before state and federal trial and appellate courts, and before arbitrators. He has also successfully litigated before the Patent Trial and Appeal Board (PTAB) in post-grant proceedings that involve patent validity. He also maintains an active patent procurement and due diligence practice. In his graduate work, Mike focused on cancer research at the cellular level, specifically in the areas of cell cycles, cell migration, and cancer metastasis. Mike earned an M.S. in genome sciences from National Yang-Ming University in Taiwan and a J.D. from U.C. Berkeley, School of Law.



**Greg Scott**

*Founder and Chairman*

**Greg Scott** founded ChinaBio® Group in 2007 to help life science companies and investors achieve success in China. ChinaBio® works with US, European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China. ChinaBio® has also organized over 30 conferences in China focused on cross-border investment and partnering, including the ChinaBio® Partnering Forum which draws over 1400 attendees from around the world to China each spring. Greg is also co-founder of two investment groups that have funded over 50 biotechnology and medical device companies in the US and China, and Executive Editor of *ChinaBio® Today*, a widely read newsletter covering the China life science industry. He also is the current chair for the American Chamber of Commerce Healthcare Committee, and a former board member of BayHelix Group. Greg is considered a leading expert on China's life science industry and is frequently quoted in media including the Wall Street Journal, Financial Times, Bloomberg, BioWorld, BioCentury, and other industry publications. Headquartered in Shanghai, ChinaBio® has team members in San Diego, Palo Alto, and Basel, Switzerland.



**Jiangwen Majeti, PhD,  
MBA**  
*Global Category  
Leader*

Jiangwen Majeti Ph.D., M.B.A. has over 15 years R&D experience in the biopharmaceutical industry. As a Global Category Leader, Jiangwen is responsible for developing and executing Roche's global outsourcing strategy in Biomarker and Companion Diagnostics for clinical development. Previously, Jiangwen served as Senior Director of Business Development at PPD, where she combined her business training and research experience to support preclinical outsourcing. Prior to this, Jiangwen was a Senior Scientist at Amgen Inc., where she successfully led research efforts in both small molecule and biologics drug discovery programs. Before Amgen, Jiangwen also worked as a Scientist at GPC Biotech and led the development of LeadCode© Technology to enable faster drug IND filing.





**Mike (Yiding) Chen,**  
*Founder and CEO*

**Mike (Yiding) Chen** previously worked as application scientist and project manager at Life Technologies and Thermofisher. Mike Chen founded ACROBiosystems in 2010, a biotech company that is committed to providing high quality protein reagent products with unique protein labeling technologies, specially designed for antibody drug development. The company keeps focusing on timely addressing needs of customers from over 60 countries. Mike Chen has over 15 years experience in pharmaceutical and biotech industry, developed the first serum-free cell culture process for rabies vaccine production in China. He has led the company to market their products to over 60 countries



**Connie Sun, Ph.D.**  
*SVP, Business &  
Corporate Development*

**Connie Sun** is Senior Vice President of Business & Corporate Development at Pharmaron. She is responsible for cross-functional business and corporate development, partnership alliance management and program management. Prior to joining Pharmaron, she has 16 years of drug discovery and development experience at biotech and pharma companies. She is author of 35 publications and inventor of 47 patents and is an inventor of Sutent<sup>®</sup>, which is currently marketed by Pfizer. She previously held positions as Head of Chemistry at Poniard Pharmaceuticals, Senior Director at AGY Therapeutics Inc. and Director of Chemistry at Pfizer (SUGEN). Connie holds a Ph.D. in Medicinal Chemistry from University of North Carolina, Chapel Hill, North Carolina. Her postdoc training was at Parke-Davis, Warner-Lambert (later Pfizer), Ann Arbor, MI.



## **JOINN Biologics**



**Tao He, PhD**  
*Co-Founder and SVP*

**Tao He** is the co-founder of JOINN Biologics US Inc., a premier CDMO dedicated to biologics development and manufacturing. He has over 20+ years' experience in pharma/biotech (Novartis, Celera Genomics, Wyeth, and Pfizer) and is an expert in protein-based drug discovery and development. He commands in-depth knowledge and experience with managing biologics development programs and is widely recognized as an industry leader and senior subject matter expert in the field of protein analytics. Tao was a pioneer in establishing developability assessment for biologics development and was a key note speaker at Bioprocessing Summit. As a project lead, he led and supported multiple biologics programs from preclinical through IND filing. Tao received his Ph.D. from University of Maryland and coauthored over 25 peer reviewed publications and nine granted patents



Cheni Kwok PhD, CLP, Managing Partner and Founder, Linear Dreams

Dr. Kwok is a senior biopharmaceutical executive with broad operational expertise who has executed over 150 transactions including M&A, strategic partnerships, licensing, divestitures, spin-offs and project financing. Dr. Kwok is the Managing Partner and Founder of Linear Dreams LLC, a management consultancy for the life sciences industry. The firm's engagements include a broad range of business and corporate development activities including managing business development teams, product and technology licensing, search & evaluation of products and technology platforms, merger & acquisitions, corporate strategy, portfolio planning, market and competitive intelligence, due diligence support for financing as well as valuation

services for 45 biopharmaceuticals companies, contract research & non-profit organizations, research institutes and investors in USA, Europe, China, Taiwan and Singapore.

As Senior Vice President, Corporate Development at Poniard Pharmaceuticals Inc., Dr. Kwok established corporate and business development, strategic and commercial planning, new product planning, competitive intelligence and forecasting functions. Previously, she was Director of Business Development at Celera Genomics Inc., where she led the business development efforts for Celera's small molecule therapeutics, including the divestiture of the oncology pipeline (including Imbruvica® (ibrutinib)) to Pharmacyclics Inc. (now

an AbbVie Company). Dr. Kwok held business development positions of increasing responsibility at Exelixis Inc., where she initiated multiple partnerships and served as the alliance manager for the GlaxoSmithKline

PLC (GSK) collaboration. Prior to joining Exelixis Inc., she held various research management, technology assessment and alliance management roles at SmithKline Beecham PLC (now GSK).

Dr. Kwok received a bachelor's degree with first class honors in biotechnology from the Imperial College of Science, Technology and Medicine, University of London, UK, a Ph.D. in human molecular genetics from the University of Cambridge, UK and has earned the Certified Licensing Professional (CLP) credential. At present, Dr. Kwok is serving as the Board of Directors of Chinese-American Biopharmaceutical Society (CABS) and serves on the Standards, Admissions & Recertification committee of Certified Licensing Professionals, Inc..

**Cheni Kwok, PhD, CLP**  
*Managing Partner  
and Founder*



**Jingrong Jean Cui, PhD**  
*Scientific Founder and  
CSO*

**Jingrong Jean Cui**, is the Scientific Founder, Director, and Chief Scientific Officer at Turning Point Therapeutics (TP). Dr. Cui is an internationally renowned oncology drug designer with more than 20 years of experience in drug discovery and project management at major pharmaceutical and biotech companies. At TP, Dr. Cui has been focusing on addressing drug resistance issue in precision medicine, an urgent unmet medical need in oncology. Currently, TP's lead clinical compound TPX-0005 (Repotrectinib) is in Phase 1/2 clinical trial and two other pipeline projects are expected to enter clinical development in 2019. Prior to TP, Dr. Cui was Associate Fellow at Pfizer and she is the lead inventor for Pfizer's oncology drugs Xalkori™ (crizotinib) and Lorbrena™ (lorlatinib). Dr. Cui also designed Pfizer's clinical compound PF-04217903 for c-MET program and participated in development of oncology drug SUTENT.

Dr. Cui is the author of more than 60 scientific publications and patents. Among them, the patent for Crizotinib (US patent 7858643) won the 38th National Inventor of the Year Award in 2011. This highly prestigious award is selected by Intellectual Property Owners Association to recognize a high impact invention in U.S. Each year, only one patent across all industries is selected for this special award. Dr. Cui was a winner of the 2013 American Chemical Society's Heroes of Chemistry Award. She was the winner of the inaugural CABS K. Fong Award in Life Sciences in 2013. For her significant accomplishments at Pfizer, Dr. Cui received Pfizer's Worldwide Research and Development Achievement Awards in 2006 and 2012, and Innovation Award in 2011.

Dr. Cui obtained her Ph.D. in Organic Chemistry from The Ohio State University and her postdoctoral training at University of California, Berkeley. Dr. Cui received her B.S. and M.S. from the University of Science and Technology of China.



**Mark Nevins, MS, MBA**

*VP, Business  
Development*

**Mark Nevins** currently serves as Vice President, Business Development of Apexigen. Prior to joining Apexigen, Mr. Nevins served as Director, Business Development at Aradigm Corp., and at Abgenix, Inc. and held positions of increasing business development responsibility at G. D. Searle & Co, the pharmaceutical subsidiary of Monsanto Company.

Mr. Nevins has more than 35 years of pharmaceutical industry experience; nearly 20 of those years have been devoted to business development and licensing. He has negotiated license agreements and strategic alliances, managed research collaborations, and, while at Abgenix, he participated in the transformative strategic alliance with AstraZeneca for the development of antibodies against multiple oncology targets. Earlier in his career, he conducted drug discovery research for G. D. Searle & Co. Mr. Nevins holds a Master's Degree in Psychology from Central Michigan University and an MBA from Dominican University.



**Yanyan Zheng, PhD**  
*Principle Scientist*

**Yanyan Zheng** is currently a Principal Scientist in Discovery Oncology at Merck & Co. Inc., leading the tumor intrinsic targeting and translational pathology group. As a seasoned drug hunter, she is interested in bringing innovative therapeutics to patients with unmet medical need. Her expertise encompasses a broad range of processes in drug development, from target identification/validation, biologics discovery, to translational research. Dr. Zheng received her Ph.D. in Molecular Microbiology and Immunology, with a concurrent M.S. degree in Biostatistics, from University of Southern California. She conducted her Postdoctoral Fellowship training in Cancer Biology at Stanford University..



**Peiwen Yu, PhD**  
*Vice President,  
Discovery Biology*

**Peiwen Yu**, currently serves as Vice President, Discovery Biology at Exelixis, Inc. Dr. Yu has been an Exelixis veteran for more than 17 years joining the company in 2001 with a successful track record of her work on cabozantinib and cobimetinib. Dr. Yu began her Exelixis career as a drug discovery Scientist, rose through the ranks, and extended her work experience from discovery to development. During her Exelixis tenure in 2012-2014, she was Senior Director of Medical Affairs and primarily managed the IST & CTEP trials, the compassionate use and single patient IND for cabozantinib, and several preclinical partnerships. From 2015-2017 during a brief break from Exelixis, Dr. Yu joined OBI Pharma as Vice President of Translational Research. At OBI, she established the Translational Medicine department, led the oncology vaccine pipeline, implemented a management matrix to oversee the in-house research projects, supported clinical trial design and data analysis, and led scientific due diligence efforts to support external licensing deals and partnerships. In 2017 she returned to Exelixis where she rebuilt the discovery biology department which includes the compound repository, high-throughput screening, tumor biology, and pharmacology groups.

Although the majority of her career was spent at Exelixis, Dr. Yu started her career in industry at Rigel, Inc., and Hoffman-La Roche where she finished her post-doctoral research fellowships. The combination of that work provided Dr. Yu with more than 20 years of extensive experience in oncology drug discovery and development, immuno-oncology, inflammation, translational medicine, and medical affairs.

Dr. Yu received her Ph.D. in Immunology/Pathobiological Sciences from University of Wisconsin-Madison, BS and MS from National Taiwan University, and studied EMBA at NCCU 2016-2017. She also served as a president of the Chinese Bioscience Association in 2012; and a board director of TFGHAA-NC in 2010-2011.



**Tara Arvedson**

*Director of Research*

**Tara Arvedson** is a researcher and team leader in the Oncology Research department at Amgen. She received her Ph.D. at Caltech and was later a Damon Runyon Cancer Research Fellow at UC San Diego. Since being at Amgen she has led multiple programs targeting benign and malignant hematology using both large and small molecules. These programs have progressed from discovery stage to the clinic.





**Wenfeng Xu, PhD**

*VP of Research*

Wenfeng Xu is currently the Vice President of Research at Hengenix Biotech, affiliated to Shanghai Henlius Biotech, a top biopharma company in China. Hengenix has a successful track record in moving multiple research leads into clinical stage with quality and speed, including the first biosimilar approval in China, 2 NDA filings and 27 IND approval in 9 years. Our goal is to accelerate the discovery and development of innovative biologics, and build a diversified and differentiated immuno-oncology portfolio.

Dr. Xu started his industrial career at ZymoGenetics in 1997, as part of the team to discover several cytokines and immune receptors (e.g. IL20, IL21, IL22, BAFF, IFN-lambda, TIGIT, B7H6, co-inventor of 37 issued US patents). He joined Novo Nordisk in 2008 as Director of Molecular Immunology, built a team to provide molecular technologies and antibody expertise for target validation and trial support in the area of autoimmune and inflammatory diseases. Prior to joining Hengenix last year, he became Associate Director of BioAnalytical Sciences at Genentech in 2015, and his group focused on driving bioanalytical strategies and providing PK/ADA/biomarker assays for Cancer Immunotherapy clinical projects.

Wenfeng was the recipient of Genentech Development Sciences “the Power of We award” for cross-functional partnership and collaboration in 2017, ZymoGenetics “Eureka award” for outstanding scientific breakthrough in 2003, and Chinese Academy of Sciences “the First Place Science award” in 1998. He received his bachelor’s degree in Biochemistry at Fudan University, Ph.D. in Molecular Biology at Chinese Academy of Sciences, and postdoctoral training at University of Washington in Seattle.